Feb 5 (Reuters) - Cognizant Technology Solutions (CTSH.O), opens new tab forecast annual revenue below estimates on Wednesday, as uncertainty about the path of future interest rate cuts forces ...

Cognizant expects its 2025 revenue to be between $20.3 billion and $20.8 billion, lower than estimates of $20.89 billion. It ...

Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to unlock even greater value for Gilead as it advances ...

As part of the multi-year renewal agreement, Cognizant is providing a dedicated team of Medidata Platform specialists to support their clients in pharmaceutical, biotech, medical device ...

Mizuho analyst Dan Dolev raised the firm’s price target on Cognizant (CTSH) to $87 from $84 and keeps a Neutral rating on the shares following the Q4 report. The firm says it is encouraged by ...

TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD ...

Cognizant is one of the leading IT services providers in the world, with products focusing on software development, including application development and maintenance, systems integration, and ...

Cognizant expects its 2025 revenue to be between $20.3 billion and $20.8 billion, lower than estimates of $20.89 billion. It projected 2025 adjusted earnings between $4.90 per share and $5.06 per ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/cognizant-reports-fourth-quarter-and-full-year-2024-results-302369335.html ...